Zevra Therapeutics, Inc.
ZVRA
$7.98
-$0.23-2.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2,510.68% | 91.33% | -7.57% | -66.75% | -19.87% |
| Total Depreciation and Amortization | 0.12% | 0.06% | 1.92% | 3.52% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101,030.56% | -99.68% | 65.29% | 1,874.93% | 172.52% |
| Change in Net Operating Assets | -6.50% | -42.20% | -1,913.81% | 83.40% | -872.97% |
| Cash from Operations | 56.20% | 49.40% | 10.42% | 5.07% | -18.21% |
| Capital Expenditure | -115.15% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.15% | 294.50% | 82.55% | -24,205.43% | -100.87% |
| Cash from Investing | 13.20% | 292.69% | 82.55% | -24,205.43% | -100.87% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 100.00% | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -30.22% | 148.62% | -98.77% | 13,392.71% | -60.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -14.06% | 101.88% | -98.77% | 322.47% | 1,159.65% |
| Foreign Exchange rate Adjustments | 276.88% | -155.44% | 236.66% | -253.92% | 808.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 191.76% | 117.55% | -237.05% | 511.79% | -1,694.50% |